Print

California Stem Cell, Inc. and Stemina Biomarker Discovery Announce Collaboration to Validate Effectiveness of Human Embryonic Stem Cell-Derived Cardiomyocyte Progenitors for Use in Predictive Toxicology  
9/17/2009 10:06:30 AM

IRVINE, Calif.--(BUSINESS WIRE)--Collaboration between California Stem Cell, Inc. (CSC) and Stemina Biomarker Discovery on a study using CSC’s 96-well CardioPlateTM containing high purity human embryonic stem cell (hESC)-derived cardiomyocyte progenitor cells, has demonstrated that it can be used as a model system for investigating and predicting drug induced cardiotoxicity, officials from the firms announced today.
//-->